Abstract
There is increasing evidence that androgen therapy in men may be effectively applied in several conditions to improve well being and health. Classical indications for androgen therapy in men may be effectively applied in several conditions to improve well being and health. Classical indications for androgen therapy in males are represented by primary or secondary hypogonadism, delayed puberty, aplastic anemia and that secondary to chronic renal failure, protein wasting diseases such as trauma, burns, tumors and infectious diseases. Androgen innovating applications in men are represented by aging and visceral obesity associated with the metabolic syndrome. In addition, it is clear that appropriate testosterone treatment can be adequately used in male contraception, provided spermatogenesis is abolished and tolerability is adequate. Due to unphysiological hormone levels achieved by currently available testosterone preparations, new delivery systems have been produced to achieve more physiological and sustained hormone levels and improve tolerability and action at the levels of target tissues. Some of them are now available in several countries and new formulas are under development.
Similar content being viewed by others
References
Wilson J.D., Griffin J.E. The use and misuse of androgens. Metabolism 1980, 29: 1278–1295.
Schally A.V., Arimura A., Kastin A.J. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971, 173: 1036–1038.
Sharpe R.M. Regulation of spermatogenesis. In: Knobil E., Neill J.D. (Eds.), The physiology of reproduction. Raven Press, New York, 1994, vol. 1, p. 1363–1434.
Anderson R.A., Wallace E.H., Groome N.P., Bellis A.J., Wu F.C.U. Physiological relationship between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone. Hum. Reprod. 1997, 12: 746–751.
Luke M.C., Coffey D.S. The male sex accessory tissues: structure, androgen action, and physiology. In: Knobil E., Neill J.D. (2 Eds.), The physiology of reproduction. Raven Press, New York, 1994, vol. 1, p. 1435–1487.
Mooradian A.D., Morley J.E., Korenman S.G. Biological actions of androgens. Endocr. Rev. 1987, 8: 1–28.
Bardin C.W., Swerdloff R.S., Santen R.J. Androgens: risks and beneficts. J. Clin. Endocrinol. Metab. 1991, 73: 4–7.
Dickinson P., Zinneman H.H., Swaim W.R., Doe R.P., Seal U.S. Effects of testosterone treatment on plasma proteins and amino acids in men. J. Clin. Endocrinol. Metab. 1969, 29: 837–841.
Solvom A. Effect of androgens on serum lipids and lipoproteins. Lipids 1980, 51: 1335–1337.
Heiss G., Tamir I., Davis C.E. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1980, 61: 302–315.
Kirkland R.T., Keenan B.S., Probstfield J.D., Patsch W., Lin T.L., Clayton G.W., Insull W. Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence: correlation with plasma testosterone levels. JAMA 1987, 257: 502–507.
Sorva R., Kuusi T., Taskinen M.R., Perheentupa J., Nikkila E.A. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988, 69: 191–197.
Root A., Steinberger E., Smith K. Isosexual pseudoprecocity in a 6-year-old boy with a testicular interstitial cell adenoma. J. Pediatr. 1972, 80: 264–268.
Santulli R., Sprando R.L., Awoniyi C.A., Ewing L.L., Zirkin B.R. To what extent can spermatogenesis be maintained in the hypophysectomized adult rat testis with exogenously administered testosterone? Endocrinology 1990, 126: 95–101.
O’Donnel L., McLachlan R.I., Wreford N.G., De Kretser D.M., Robertson D.M. Testosterone withdrawal promotes stage-specific detachment of round spermatids from the seminiferous epithelium. Biol. Reprod. 1996, 55: 895–901.
Tesarik J., Guido M., Mendoza C., Greco E. Human spermatogenesis in vitro: respective effects of follicle-stimulating hormone and testosterone on meiosis, spermiogenesis, and Sertoli cell apoptosis. J. Clin. Endocrinol. Metab. 1998, 83: 4467–4473.
Erkkila K., Henriksen K., Hirvonen V., Rannikko S., Salo J., Parvinen M., Dunkel L. Testosterone regulates apoptosis in adult human seminiferous tubules in vitro. J. Clin. Endocrinol. Metab. 1997, 82: 2314–2321.
Berg J.P. Oestrogens-essentials for reproduction in males, too. Eur. J. Endocrinol. 1998, 138: 497–498.
Forbes G.B. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 1985, 34: 571–573.
Young N.R., Baker H.W.G., Liu G., Seeman E. Body composition and muscle strenght in healthy men receiving testosterone enanthate for contraception. J. Clin. Endocrinol. Metab. 1993, 77: 1028–1032.
Ammus S.S. The role of androgens in the treatment of hematologic disorders. Adv. Intern. Med. 1989, 34: 191–208.
Gardner F.H., Nathan D.G., Piomelli S., Cummins J.F. The erythrocythaemic effects of androgens. Br. J. Haematol. 1968, 14: 611–615.
Bagatell C.J., Matsumoto A.M., Christenses R.B., Rivier J.E., Bremner W.J. Comparison of gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. 1993, 77: 427–432.
Bizzarro A., Valentini G., Di Martino G., Da Ponte A., De Bellis A., Iacono G. Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter’s syndrome. J. Clin. Endocrinol. Metab. 1987, 64: 32–36.
Finkelstein J.S., Klibanski A. Effects of androgens on bone metabolism. In: Nieschlag E.B., Behre H.M. (Eds.), Testosterone: action, deficiency, substitution. Springer, Germany, 1990, p. 204–218.
Finkelstein J.S., Klibanski A., Neer R.M., Greenspan S.L., Rosenthal D.I., Crowley W.E.Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med. 1987, 106: 354–361.
Jackson J.A., Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine (Baltimore) 1990, 69: 137–152.
Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 1997, 82: 2386–2390.
Eriksen E.F., Colvard D.S., Berg N.J., Graham M.L., Mann K.G., Spelsberg T.C., Riggs B.L. Evidence of estrogen receptors in normal human osteoblast- like cells. Science 1988, 241: 84–86.
Tanaka S., Haji M., Nishi Y., Yanase T., Takayanagi R., Nawata H. Aromatase activity in human osteoblast-like osteosarcoma cell. Calcif. Tissue Int. 1993, 52: 107–109.
Carani C., Simoni M., Faustini-Fustini M., Serpente S., Boyd J., Korach K.S., Simpson E.R. Aromatase deficiency in the male: effect of testosterone and estradiol treatment. N. Engl. J. Med. 1997, 337: 91–95.
Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., Williams T.C., Lubahn D.B., Korach K.S. Estrogen resistance caused by a mutation in the estrogen- receptor gene in a man. N. Engl. J. Med. 1994, 331: 1056–1061.
Bagatell C.J., Heiman J.R., Rivier J.E., Bremner W.J. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J. Clin. Endocrinol. Metab. 1994, 78: 711–716.
Davidson J.M., Kwan M., Greenleaf W.J. Hormonal replacement and sexuality in men. Clin. Endocrinol. Metab. 1982, 11: 599–623.
Gooren L.J. Androgen levels and sex functions in testosteronetreated hypogonadal men. Arch. Sex. Behav. 1987, 16: 463–473.
Salmimies P., Kockott G., Pirke K.M., Vogt H.J., Schill W.B. Effects of testosterone replacement on sexual behavior in hypogonadal men. Arch. Sex. Behav. 1982, 11: 345–353.
Davidson J.M., Camargo C.A., Smith E.R. Effects of androgens on sexual behaviour in hypogonadal men. J. Clin. Endocrinol. Metab. 1979, 48: 955–958.
Kwan M., Greenleaf W.J., Mann J., Crapo L., Davidson J.M. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J. Clin. Endocrinol. Metab. 1983, 57: 557–562.
O’Carroll R., Shapiro C., Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin. Endocrinol. (Oxf.) 1985, 23: 527–538.
Skakkebaek N.E., Bancroft J., Davidson D.W., Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin. Endocrinol. (Oxf.) 1981, 14: 49–61.
Michael R.P., Zumpe D. Annual cycles of aggression and plasma testosterone in captive male rhesus monkeys. Psychoneuroendocrinology 1978, 3: 217–220.
Su T.P., Pagliaro M., Schmidt P.J., Pickar D., Wolkowitz O., Rubinow D.R. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993, 269: 2760–2764.
Anderson R.A., Bancroft J., Wu F.C. The effects of exogenous testosterone on sexuality and mood of normal men. J.Clin. Endocrinol. Metab. 1992, 75: 1503–1507.
Bagatell C.J., Heiman J.R., Matsumoto A.M., Rivier J.E., Bremner W.J. Metabolic and behavioral effects of high dose, exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 1994, 79: 561–567.
Honrath W.L., Wolff A., Meli A. The influence of the amount of solvent (sesame oil) on the degree and duration of action of subcutaneously administered testosterone and its propionate. Steroids 1963, 2: 425–428.
James K.C., Nicholls P.J., Roberts M. Biological half-lives of 4-14C testosterone and some of its esters after injection into the rat. J. Pharm. Pharmacol. 1969, 21: 24–27.
Snyder P.J., Lawrence D.A. Treatment of male hypogonadism with testosterone enanthate. J. Clin. Endocrinol. Metab. 1980, 51: 1335–1339.
Sokol R.Z., Palacios A., Campfield L.A., Saul C., Swerdloff R.S. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil. Steril. 1982, 37: 425–430.
Alkalay D., Khemani L., Wagner W.E. Sublingual and oral administration of methyltestosterone. A comparison of drug bioavailability. J. Clin. Pharmacol. 1973, 13: 142–151.
Foss G.L. A comparison of the relative efficacy of methyltestosterone by the gastric and oral transmucosal routes. J. Endocrinol. 1956, 13: 269–273.
Mosbach E.H., Shefer S., Abell L.L. Identification of the fecal metabolites of 17 alfamethyltestosterone in the dog. J. Lipid. Res. 1968, 9: 93–97.
Segaloff A., Gabbard R.B., Carriere B.T. The metabolism of 4-14C-17 alfa-methyltestosterone. Steroids 1965, 1 (Suppl.): 149–158.
Alkalay D., Khemani L., Bartlett M.F. Spectrophotofluorometric determination of methyltestosterone in plasma or serum. J. Pharm. Sci. 1972, 61: 1746–1749.
Gooren L.J. A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. 1994, 15: 212–215.
Cunningham G.R., Cordero E., Thornby J.I. Testosterone replacement with transdermal therapeutic systems. JAMA 1989, 261: 2525–2530.
Wilson J.D., Walker J.D. The conversion of testosterone to 5a-androstane-17β- ol-3 one (dihydrotestosterone) by skin slices of man. J. Clin. Invest. 1969, 48: 371–379.
Behre H.M., Bohmeyer J., Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to agematched normal controls. Clin. Endocrinol. (Oxf.) 1994, 40: 341–349.
Meikle A.W., Arver S., Dobs A.S., Sanders S.W., Rajaram L., Mazer N.A. Pharmacokinetics and metabolism of a permeation enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81: 1832–1840.
Meikle A.W., Mazer N.A., Moellmer J.F., Stringham J.D., Tolman K.G., Sanders S.W., Odell W.D. Enhanced transdermal delivery of testosterone across the non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J. Clin. Endocrinol. Metab. 1992, 74: 623–628.
Mazer N.A., Sanders S.W., Ebert C.D., Meikle A.W. Mimicking the circadian pattern of testosterone and metabolite levels with an enhanced transdermal delivery system. In: Gurney R., Junginger H.E., Peppas N. (Eds.), Pulsatile drug delivery: current applications and future trends. Stuttgart, Wissenshaftliche Verlagsgesellschaft mbH, 1993, p. 73–97.
Meikle A.W., Arver S., Dobs A.S., Sanders S.W., Mazer N.A. Androderm: a permeation enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: Bhasin S. (Ed.), Pharmacology, biology, and clinical applications of androgens. Wiley-Liss, New York, 1996, p. 449–457.
Handelsman D.J., Conway A.J., Boyan L.M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J. Clin. Endocrinol. Metab. 1990, 71: 216–222.
Bhasin S., Swerdloff R.S., Steiner B., Peterson M.A., Meridores T., Galmirini M., Pandian M.R., Goldberg R., Berman N. A biodegradable testosterone microsphere formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men. J. Clin. Endocrinol. Metab. 1992, 74: 75–83.
Behre H.M., Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocrinol. Metab. 1992, 75: 1204–1210.
Behre H.M., Nieschlag E. Comparative pharmacokinetics of testosterone esters. In: Nieschlag E., Behre H.M. (Eds.), Testosterone: Action-Deficiency-Substitution. Springer, Germany, 1998, p. 329–348.
Uekama K., Otagiri M. Cyclodextrin in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 1987, 3: 1–40.
Brewster M.E., Estes K.S., Loftsson T. Improved delivery through biological membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified b-cyclodextrin. J. Pharm. Sci. 1988, 77: 981–985.
Stuenkel C.A., Dudley R.E., Yen S.S.C. Sublingual administration of testosterone-hydroxypropyl- beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J. Clin. Endocrinol. Metab. 1991, 72: 1054–1059.
Partsch C.J., Weinbauer G.F., Fang R., Nieschlag E. Injectable testosterone undecanoate has more favorable pharmacokinetics and pharmacodynamics than testosterone enanthate. Eur. J. Endocrinol. 1995, 132: 514–519.
Dobs A.S., Hoover D.R., Chen M.C., Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J. Clin. Endocrinol. Metab. 1998, 83: 33–39.
Bagatell C.J., Bremner W.J. Androgens in men-uses and abuses. N. Engl. J. Med. 1996, 334: 707–714.
Zgliczynski S., Ossowski M., Slowinska-Srzednicka J., Brzezinska A., Zgliczynski W., Soszynski P., Chotkowska E., Srzednicki M., Sadowski Z. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996, 121: 35–43.
Snyder P.J. Clinical use of androgens. Annu. Rev. Med. 1984, 35: 207–217.
Richman R.A., Kirsch L.R. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N. Engl. J. Med. 1988, 319: 1563–1567.
Butler G.E., Sellar R.E., Walker R.F. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J. Clin. Endocrinol. Metab. 1992, 75: 37–44.
Bourguignon J.P. Linear growth as a function of age at onset of puberty and sex steroid dosage: therapeutic implications. Endocr. Rev. 1988, 9: 467–488.
Rissanen A., Heliovaara M., Knekt P., Reunanen A., Aromaa A., Maatila J. Risk of disability and mortality due to overweight in a Finnish population. Br. Med. J. 1990, 301: 835–837.
Wannamathaa G., Shaper A.G. Body weight and mortality in middle-aged British men. Br. Med. J. 1989, 299: 1497–1502.
Vague J. The degree of masculine differentiation of obesities. Am. J. Clin. Nutr. 1956, 4: 20–21.
Hartz A.J., Rupley D.C., Rimm A.A. The association of girth measurement with disease in 32.856 women. Am. J. Epidemiol. 1984, 119: 71–80.
Kissebah, Vydelingum N., Murray R. Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 1982, 54: 254–260.
Bjorntorp P. Visceral obesity: a “Civilization Syndrome”. Obes. Res. 1993, 1: 206–222.
Vague J. La differentiation sexuelle. Facteur determinant des formes de l’obesitè. Presse Med. 1947, 55: 339–341.
Glass A.R., Swerdloff R.S., Bray G.A., Dahms W., Atkinson R.S. Low serum testosterone sex hormone binding globulin in massively obese men. J. Clin. Endocrinol. Metab. 1977, 45: 1211–1219.
Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Morselli-Labate A.M., Fabbri R., Capelli M., Bortoluzzi L. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991, 40: 101–104.
Vermeulen A., Kaufman J.M., Desslijpere J.P., Thomas G. Attenuated LH pulse amplitude but normal LH pulse frequency and its relation to plasma androgens in hypogonadism of obese men. J. Clin. Endocrinol. Metab. 1993, 76: 1140–1146.
Plymate S.R., Matej L.A., Jones R.E. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J. Clin. Endocrinol. Metab. 1988, 67: 460–464.
Nestler J.E. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J. Clin. Endocrinol. Metab. 1993, 76: 273–274.
Pasquali R., Casimirri F., De Iasio R., Mesini P., Boschi S., Chierici R., Flamia R., Biscotti D., Vicennati V. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J. Clin. Endocrinol. Metab. 1995, 80: 654–658.
Pasquali R., Casimirri F., Cantobelli S., Buratti P., Bortoluzzi L., Capelli M., Morselli Labate A.M., Barbara L. Beta-endorphin response to exogenous corticotrophin- releasing hormone in obese women with different patterns of body fat distribution. Int. J. Obes. 1993, 17: 593–596.
Pasquali R., Cantobelli S., Casimirri F., Bortoluzzi L., Boschi S., Capelli M., Melchionda N., Barbara L. The role of the opioid peptides in the development of hyperinsulinemia in obese women with abdominal body fat distribution. Metabolism 1992, 41: 763–767.
Iranmanesh A., Lizarralde G., Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 1991, 73: 1081–1088.
Bjorntorp P. The regulation of adipose tissue distribution in humans. Int. J. Obes. 1996, 20: 291–302.
De Pergola G., Xu X., Yang S., Giorgino R., Bjorntorp P. Up-regulation of androgen receptor binding in male rat fat pad adipose precursor cells exposed to testosterone: study in a whole cell assay system. J. Steroid Biochem. Mol. Biol. 1990, 37: 553–558.
Rebuffè-Scrive M., Marin P., Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int. J. Obes. 1991, 15: 791–795.
Xu X., De Pergola G., Bjorntorp P. Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991, 128: 379–382.
Xu X., De Pergola G., Bjorntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990, 126: 1229–1234.
Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., Lindsted G., Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-age obese men. Int. J. Obes. 1992, 16: 991–997.
Seidell J., Bjorntorp P., Sjostrom L., Kvist H., Sannerstedt R. Visceral fat accumulation in men positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metabolism 1990, 39: 897–901.
Barett-Connor E., Khaw K-T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988, 78: 539–545.
Haffner S.M., Katz M.S., Stern M.P., Dunn J.F. The relationship of sex hormones to hyperinsulinemia and hyperglycemia. Metabolism 1988, 37: 683–688.
Mårin P. Effects of androgens in men with the metabolic syndrome. The Aging Male 1998, 1: 129–136.
Vermeulen A. Androgens in the aging male. J. Clin. Endocrinol. Metab. 1991, 73: 221–224.
Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospectives analysis. J. Clin. Endocrinol. Metab. 1997, 82: 3793–3796.
Morley J.E., Perry H.M. III, Kaiser F.E., Kraenzle D., Jensen J., Houston K., Mattammal M., Perry H.M. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. Soc. 1993, 41: 149–152.
Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 1992, 75: 1092–1098.
Sih R., Morley J.E., Kaiser F.E., Perry H.M. III, Patrick P., Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 1997, 82: 1661–1667.
Schiavi R.C. Androgens and sexual function in men. In: Oddens B., Vermeulen A. (Eds.), Androgens and the aging male. Parthenon Publishing Group, New York, 1996, p. 111–113.
Lugg J., Rajfer J., Gonzales-Cadavit N.F. Dihydrotestosterone is the active androgen in the maintenance of nitric-oxide mediated penile erection in the rat. Endocrinology 1995, 136: 1495–1501.
Clopper R.R., Voorhess M.L., MacGillivray M.H., Lee P.A., Mills B. Psychosexual behavior in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement. Psychoneuroendocr. 1993, 18: 149–161.
Matsumoto A.M., Bremner W.J. Endocrine control of human spermatogenesis. J. Steroid Biochem. 1989, 33: 789–790.
Matsumoto A.M., Karpas A.E., Paulsen C.A. Reinitiation of sperm production in gonadotropin-suppressed men by administration of follicle stimulating hormone. J. Clin. Invest. 1983, 72: 1005–1015.
Weinbauer G.F., Gockeler E., Nieschlag E. Testosterone prevents the complete suppression of spermatogenesis in the gonadotropin-releasing hormone (GnRH) antagonist-treated non-human primate (Macaca Fascicularis). J. Clin. Endocrinol. Metab. 1988, 67: 284–290.
Sharpe R.M., Donachie K., Cooper I. Re-evaluation of the intratesticular level of testosterone required for quantitative maintenance of spermatogenesis in the rat. J. Endocrinol. 1988, 117: 19–26.
Weinbauer G.F., Nieschlag E. The leydig cell as a target for male contraception. In: Payne A.H., Hardy H.P., Russell L.D. (Eds.), The Leydig cell. Cache River Press, Vienna, 1996, p. 629–662.
Cummings D.E., Bremner W.J. Prospects for new hormonal male contraceptives. Clin. Endocrinol. Metab. North Am. 1994, 23: 893–922.
World Health Organization task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990, 336: 955–959.
World Health Organization task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. 1996, 65: 821–829.
Meriggiola M.C., Bremner W.J. Progestin-androgen combination regimens for male contraception. J. Andrology 1997, 18: 240–244.
Meriggiola M.C., Marcovina S., Paulsen C.A., Bremner W.J. Testosterone enanthate at the dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int. J. Androl. 1995, 18: 237–242.
Handelsman D.J., Conway A.J., Boyland L.M. Suppression of human spermatogenesis by testosterone implants. J. Clin. Endocrinol. Metab. 1992, 75: 1326–1332.
Behre H.M., Bans S., Kliesch S., Keck C., Simoni M., Nieschlag E. Potential of testosterone buciclate for male contraception: endocrine differences between responders and non responders. J. Clin. Endocrinol. Metab. 1995, 80: 2394–2403.
Bremner W.J., Bagatell C.J., Steiner R.A. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive. J. Clin. Endocrinol. Metab. 1991, 73: 465–469.
Bagatell C.J., Matsumoto A.M., Christensen R.B., Rivier J.E., Bremner W.J. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. 1993, 77: 427–432.
Pavlou S.N., Brewer K., Lindner J. Combined administration of a gonadotropin releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J. Clin. Endocrinol. Metab. 1991, 73: 1360–1369.
Tom L., Bhasin S., Salameh W. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin releasing-hormone antagonist and testosterone enanthate. J. Clin. Endocrinol. Metab. 1992, 75: 476–483.
Meriggiola M.C., Bremner W.J., Paulsen C.A., Valdiserri A., Incorvaia L., Motra R., Pavani A., Capelli M., Flamigni C. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J. Clin. Endocrinol. Metab. 1996, 81: 3018–3023.
Behre H.M., Böckers A., Schlingheider A., Nieschlag E. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist Cetrorelix over 8 days in normal men. Clin. Endocrinol. (Oxf.) 1994, 40: 241–248.
Weinbauer G.F., Limberger A., Behre H.M., Nieschlag E. The GnRH antagonist cetrorelix inhibits spermatogenesis in the non-human primate: effects of delayed high dose testosterone substitution. Proceedings of the 9th International Congress of Endocrinology, Nice, France, 1992, p. 419.
Büchter D., Eckardstein S.V., Eckardstein A.V., Kamischke A., Simoni M., Behre H.M., Nieschlag E. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J. Clin. Endocrinol. Metab. 1999, 84: 1244–1249.
Neumann F. The physiological action of progesterone and pharmacological effects of progestagens. Postgrad. Med. J. 1978, 54: 11–24.
Andersson A., Edvardsen K., Skakkebaek N.E. Expression and localization of N and E-cadherin in the human testis and epididymis. Int. J. Androl. 1994, 17: 174–180.
Schneider B.K., Pickett C.K., Zwillich C.W., Weil J.V., Mc Dermott M.T., Santen R.J., Varano L.A., White D.P. Influence of testosterone on breathing during sleep. J. Appl. Physiol. 1986, 61: 618–623.
Ghusn H.F., Cunningham G.R. Evaluation and treatment of androgen deficiency in males. The Endocrinologist 1991, 1: 399–400.
Alen M., Rahkila P., Marniemi J. Serum lipids in power athletes self-administering testosterone and anabolic steroids. Int. J. Sports Med. 1985, 6: 139–144.
Friedl K.E., Hannan C.J. Jr., Jones R.E., Plymate S.R. High-density lipoprotein is not decreased if an aromatizable androgen is administered. Metabolism 1990, 39: 69–74.
Thompson P.D., Cullinane E.M., Sady S.P., Chenevert C., Saritelli A.L., Sady M.A., Herbert P.N. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989, 261: 1165–1168.
Zmuda J.M., Fahrenbach M.C., Younkin B.T., Bausserman L.L., Terry R.B., Catlin D.H., Thompson P.D. The effect of testosterone aromatization on highdensity lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism 1993, 42: 446–450.
Bhasin S., Bremner W.J. Emerging issues in androgen replacement therapy. J. Clin. Endocrinol. Metab. 1996, 82: 3–8.
Meikle A.W., Arver S., Dobs A.S., Adolfsson J., Sanders S.W., Middleton R.G., Stephenson R.A., Hoover D.R., Rajaram L., Mazer N.A. Prostate size in hypogonadal men treated with a non scrotal permeation-enhanced testosterone transdermal system. Urology 1997, 49: 191–196.
Jordan W.P. Jr. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non scrotal transdermal systems. Am. J. Contact Dermat. 1997, 8: 108–113.
Ishak K.G., Zimmerman H.J. Hepatotoxic effects of the anabolic/androgenic steroids. Semin. Liver Dis. 1987, 7: 230–236.
Gurakar A., Caraceni P., Fagiuoli S., Van Thiel D.H. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J. Okla. State Med. Assoc. 1994, 87: 399–404.
Soe K.L., Soe M., Gluud C. Liver pathology associated with the use of anabolicandrogenic steroids. Liver 1992, 12: 73–79
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gambineri, A., Pasquali, R. Testosterone therapy in men: Clinical and pharmacological perspectives. J Endocrinol Invest 23, 196–214 (2000). https://doi.org/10.1007/BF03343707
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343707